The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
2025 marked a year of significant progress of reached milestones and successes for Bloom Surgical
A microbiologist, Adam Barker, PhD, was ARUP’s chief scientific officer and director of Research and Development before being named chief operations officer—now adds Reference Business Unit president to his title.
The Australian patent represents the first patent granted for the Company’s new point-of-care testing platform.
Merit Medical’s Fred Lampropoulos Honored by Nasdaq
Perimeter Solutions Announces Agreement to Acquire MMT for $685 Million
Freyya Recognized at Transatlantic Angel Competition (TAAC8)
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Collaboration expands Owlet’s national DME footprint, strengthens access for Medicaid and TRICARE families, and supports continued growth in prescription-backed revenue channel.
In-vitro studies confirmed strong uptake of cell-targeting nanoparticles by cancer cells and strong activation of Smart mRNAs inside cancer cells
Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas